Ewing sarcoma: Current management and future approaches through collaboration

Journal of Clinical Oncology

Volumn 33, Issue 27, 2015, Pages 3036-3046

  Gaspar, Nathalie ^a,b   Hawkins, Douglas S ^f,g   Dirksen, Uta ^h,i   Lewis, Ian J ^k,l   Ferrari, Stefano ^r,s   Le Deley, Marie Cecile ^a,b,c   Kovar, Heinrich ^u,v   Grimer, Robert ^l,m   Whelan, Jeremy ^n,w   Claude, Line ^b,d   Delattre, Olivier ^b,e   Paulussen, Michael ^i,j   Picci, Piero ^r,s   Hall, Kirsten Sundby ^x,y   Van Den Berg, Hendrik ^aa,ab   Ladenstein, Ruth ^u,v   Michon, Jean ^b,e   Hjorth, Lars ^y,z   Judson, Ian ^o,w   Luksch, Roberto ^s,t   Bernstein, Mark L ^g,ac   Marec Bérard, Perrine ^b,d   Brennan, Bernadette ^l,p   Craft, Alan W ^l,q   Womer, Richard B ^g,ad   Juergens, Heribert ^h,i   Oberlin, Odile ^a,b   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Societe Francaise de Lutte Contre les Cancers et les Leucemies de L'Enfant et de L'Adolescent   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT CURIE   (France)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

^g CHILDREN S ONCOLOGY GROUP   (United States)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ Gesellschaft für Pädiatrische Onkologie und Hämatologie ^*  (Germany)

^j UNIVERSITY OF WITTEN HERDECKE   (Germany)

^k ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^l Children's Cancer and Leukaemia Group   (United Kingdom)

^m ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^o ROYAL MARSDEN HOSPITAL   (United Kingdom)

^p ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^q ROYAL VICTORIA INFIRMARY   (United Kingdom)

^r RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^s Italian Sarcoma Group   (Italy)

^t NATIONAL CANCER INSTITUTE   (Italy)

^u CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^v Arbeitsgemeinschaft Ambulant Tätiger Pädiatrischer Onkologen und Hämatologen   (Austria)

^w EORTC DATA CENTER   (Belgium)

^x OSLO UNIVERSITY HOSPITAL   (Norway)

^y Scandinavian Sarcoma Group   (Norway)

^z LUND UNIVERSITY HOSPITAL   (Sweden)

^aa EMMA CHILDREN S HOSPITAL   (Netherlands)

^ab DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^ac DALHOUSIE UNIVERSITY   (Canada)

^ad UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; EWING SARCOMA; HUMAN; LOCAL THERAPY; LUNG METASTASIS; MEDICAL ONCOLOGIST; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PEDIATRIC ONCOLOGIST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; ADOLESCENT; BONE NEOPLASMS; CHILD; COOPERATION; FORECASTING; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MASS COMMUNICATION; MORTALITY; ONCOLOGY; ONSET AGE; PEDIATRICS; SARCOMA, EWING; SURVIVOR; TIME; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADOLESCENT; AGE OF ONSET; BONE NEOPLASMS; CHILD; COOPERATIVE BEHAVIOR; DIFFUSION OF INNOVATION; FORECASTING; HUMANS; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MEDICAL ONCOLOGY; PEDIATRICS; SARCOMA, EWING; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942280113     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.5256     Document Type: Review

References (96)

1. Nesbit ME Jr, Perez CA, Tefft M, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: An Intergroup Study. Natl Cancer Inst Monogr 56:255-262, 1981
2. Burgert EO Jr, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
3. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003
4. Granowetter L, Womer R, Devidas M, et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group study. J Clin Oncol 27:2536-2541, 2009
5. Womer RB, West DC, Krailo MD, et al: Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 30:4148-4154, 2012
6. Paulussen M, Craft AW, Lewis I, et al: Results of the EICESS-92 study: Two randomized trials of Ewing's sarcoma treatment-Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26:4385-4393, 2008
7. Le Deley MC, Paulussen M, Lewis I, et al: Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 32:2440-2448, 2014
8. Bacci G, Ferrari S, Longhi A, et al: Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14:1654-1659, 2003
9. McTiernan A, Driver D, Michelagnoli MP, et al: High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol 17:1301-1305, 2006
10. Al-Faris N, Al Harbi T, Goia C, et al: Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer 49:190-195, 2007
11. Rasper M, Jabar S, Ranft A, et al: The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer 61: 1382-1386, 2014
12. Meyers PA, Krailo MD, Ladanyi M, et al: Highdose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19:2812-2820, 2001
13. Oberlin O, Rey A, Desfachelles AS, et al: Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: A study by the Société Française des Cancers de l'Enfant. J Clin Oncol 24:3997-4002, 2006
14. Ladenstein R, Pötschger U, Le Deley MC, et al: Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 28:3284-3291, 2010
15. Diaz MA, Lassaletta A, Perez A, et al: Highdose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: A long-term follow-up single-center study. Pediatr Hematol Oncol 27:272-282, 2010
16. Ferrari S, Sundby Hall K, Luksch R, et al: Nonmetastatic Ewing family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients-Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol 22:1221-1227, 2011
17. Luksch R, Tienghi A, Hall KS, et al: Primary metastatic Ewing's family tumors: Results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol 23:2970-2976, 2012
18. Ladenstein R, Valteau-Couanet D, Glogova E, et al: The role of megatherapy (MGT) and stem cell transplantation (SCT) in high risk Ewing tumors: More than 30 years of EBMT activity. Presented at the 27th Annual Meeting of the European Musculo-Skeletal Oncology Society, Vienna, Austria, May 21-23, 2014
19. Postel-Vinay S, Véron AS, Tirode F, et al: Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 44:323-327, 2012
20. Delattre O, Zucman J, Plougastel B, et al: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162-165, 1992
21. Gaspar N, Di Giannatale A, Geoerger B, et al: Bone sarcomas: From biology to targeted therapies. Sarcoma 2012:301975, 2012
22. Kovar H, Alonso J, Aman P, et al: The first European interdisciplinary ewing sarcoma research summit. Front Oncol 2:54, 2012
23. Shukla N, Schiffman J, Reed D, et al: Biomarkers in Ewing sarcoma: The promise and challenge of personalized medicine-A report from the Children's Oncology Group. Front Oncol 3:141, 2013
24. Krasin MJ, Rodriguez-Galindo C, Davidoff AM, et al: Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumors. Pediatr Blood Cancer 43:229-236, 2004
25. Göbel V, Jürgens H, Etspüler G, et al: Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 113:187-191, 1987
26. Oberlin O, Deley MC, Bui BN, et al: Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: The third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 85:1646-1654, 2001
27. Bacci G, Ferrari S, Bertoni F, et al: Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4-11, 2000
28. Jürgens H, Exner U, Gadner H, et al: Multidisciplinary treatment of primary Ewing's sarcoma of bone: A 6-year experience of a European cooperative trial. Cancer 61:23-32, 1988
29. Oberlin O, Habrand JL, Zucker JM, et al: No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10:1407-1412, 1992
30. Gaspar N, Rey A, Bérard PM, et al: Risk adapted chemotherapy for localised Ewing's sarcoma of bone: The French EW93 study. Eur J Cancer 48:1376-1385, 2012
31. Craft AW, Cotterill SJ, Bullimore JA, et al: Long-term results from the first UKCCSG Ewing's tumour study (ET-1): United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 33:1061-1069, 1997
32. Hense HW, Ahrens S, Paulussen M, et al: Factors associated with tumor volume and primary metastases in Ewing tumors: Results from the (EI)CESS studies. Ann Oncol 10:1073-1077, 1999
33. Hawkins DS, Schuetze SM, Butrynski JE, et al: [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828-8834, 2005
34. Gupta K, Pawaskar A, Basu S, et al: Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin Nucl Med 36:973-977, 2011
35. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14:1245-1251, 1996
36. de Alava E, Kawai A, Healey JH, et al: EWSFLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16:1248-1255, 1998
37. Le Deley MC, Delattre O, Schaefer KL, et al: Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: Prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 28:1982-1988, 2010
38. van Doorninck JA, Ji L, Schaub B, et al: Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 28:1989-1994, 2010
39. Lerman DM, Monument MJ, McIlvaine E, et al: Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. Presented at the Connective Tissue Oncology Society meeting, Berlin, Germany, October 15-18, 2014
40. Tirode F, Surdez D, Ma X, et al: Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 4:1342-1353, 2014
41. Specht K, Sung YS, Zhang L, et al: Distinct transcriptional signature and immunoprofile of CICDUX4 fusion-positive round cell tumors compared to EWSR1-rearranged ewing sarcomas: Further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 53:622-633, 2014
42. Cohen-Gogo S, Cellier C, Coindre JM, et al: Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: A clinical, radiological and pathological retrospective study from the Société Française des Cancers de L'Enfant. Pediatr Blood Cancer 61:2191-2198, 2014
43. Domingo-Fernandez R, Watters K, Piskareva O, et al: The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int 29:101-119, 2013
44. Fagnou C, Michon J, Peter M, et al: Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor: Société Française d'Oncologie Pediatrique. J Clin Oncol 16:1707-1711, 1998
45. Zoubek A, Ladenstein R, Windhager R, et al: Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: A preliminary evaluation. Int J Cancer 79:56-60, 1998
46. Schleiermacher G, Delattre O: Detection of micrometastases and circulating tumour cells using molecular biology technics in solid tumours [in French]. Bull Cancer 88:561-570, 2001
47. Schleiermacher G, Peter M, Oberlin O, et al: Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 21:85-91, 2003
48. de Alava E, Lozano MD, Patiño A, et al: Ewing family tumors: Potential prognostic value of reversetranscriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol 7:152-157, 1998
49. Avigad S, Cohen IJ, Zilberstein J, et al: The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 100: 1053-1058, 2004
50. Wagner LM, Smolarek TA, Sumegi J, et al: Assessment of minimal residual disease in ewing sarcoma. Sarcoma 2012:780129, 2012
51. Donaldson SS, Torrey M, Link MP, et al: A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: End results of POG #8346-Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 42:125-135, 1998
52. Paulussen M, Ahrens S, Dunst J, et al: Localized Ewing tumor of bone: Final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol 19:1818-1829, 2001
53. Ewing J: Diffuse endothelioma of bone. Proc N Y Path Soc 7:17-24, 1921
54. DuBois SG, Krailo MD, Gebhardt MC, et al: Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group. Cancer 121:467-475, 2015
55. Hardes J, von Eiff C, Streitbuerger A, et al: Reduction of periprosthetic infection with silvercoated megaprostheses in patients with bone sarcoma. J Surg Oncol 101:389-395, 2010
56. Zahlten-Hinguranage A, Bernd L, Ewerbeck V, et al: Equal quality of life after limb-sparing or ablative surgery for lower extremity sarcomas. Br J Cancer 91:1012-1014, 2004
57. Germain MA, Mascard E, Dubousset J, et al: Free vascularized fibula and reconstruction of long bones in the child: Our evolution. Microsurgery 27:415-419, 2007
58. Schuck A, Rübe C, Könemann S, et al: Postoperative radiotherapy in the treatment of Ewing tumors: Influence of the interval between surgery and radiotherapy. Strahlenther Onkol 178:25-31, 2002
59. Schuck A, Ahrens S, Paulussen M, et al: Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 55:168-177, 2003
60. Bacci G, Forni C, Longhi A, et al: Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies: 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 40:73-83, 2004
61. Hardes J, Gosheger G, Vachtsevanos L, et al: Rotationplasty type BI versus type BIIIa in children under the age of ten years: Should the knee be preserved? J Bone Joint Surg Br 87:395-400, 2005
62. Claude L, Alapetite C, Quetin P, et al: Toxicity of high-dose busulfan-melphalan chemotherapy followed by radiation therapy in Ewing's axial tumors: Preliminary results of a French quality control study. Presented at the International Society of Paediatric Oncology meeting, Geneva, Switzerland, September 17-21, 2006
63. Bölling T, Dirksen U, Ranft A, et al: Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: Review of GPOH data. Strahlenther Onkol 185:21-22, 2009 (suppl 2)
64. Shankar AG, Pinkerton CR, Atra A, et al: Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 35:1698-1704, 1999
65. Gaspar N, Brennan B, Jeys L, et al: Can postoperative radiotherapy be omitted in localized standard-risk Ewing sarcoma? An observational study of the Euro-EWING Group. J Clin Oncol 31: 636s, 2013 (suppl 15s; abstr 10518)
66. UK Clinical Trials Gateway: Euro-EWING 2012. http://www.ukctg.nihr.ac.uk/trialdetails/ISRCTN92192408
67. Smith MA, Ungerleider RS, Horowitz ME, et al: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1991
68. Carli M, Passone E, Perilongo G, et al: Ifosfamide in pediatric solid tumors. Oncology 65:99-104, 2003 (suppl 2)
69. Womer RB, Daller RT, Fenton JG, et al: Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 36:87-94, 2000
70. Ladenstein R, Hartmann O, Pinkerton CR: The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood. Ann Oncol 4:45-58, 1993 (suppl 1)
71. Paulussen M, Ahrens S, Craft AW, et al: Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) cooperative Ewing's sarcoma studies patients. J Clin Oncol 16:3044-3052, 1998
72. Heij HA, Vos A, de Kraker J, et al: Prognostic factors in surgery for pulmonary metastases in children. Surgery 115:687-693, 1994
73. Bacci G, Briccoli A, Picci P, et al: Metachronous pulmonary metastases resection in patients with Ewing's sarcoma initially treated with adjuvant or neoadjuvant chemotherapy. Eur J Cancer 31A: 999-1001, 1995
74. Juergens C, Weston C, Lewis I, et al: Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47:22-29, 2006
75. Felgenhauer JL, Nieder ML, Krailo MD, et al: A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) phase II study NCT00061893. Pediatr Blood Cancer 60:409-414, 2013
76. Rodríguez-Galindo C, Navid F, Liu T, et al: Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol 19:814-820, 2008
77. Hunold A, Weddeling N, Paulussen M, et al: Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47:795-800, 2006
78. Casey DA, Wexler LH, Merchant MS, et al: Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 53:1029-1034, 2009
79. Fox E, Patel S, Wathen JK, et al: Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration study 003. Oncologist 17:321, 2012
80. Ferrari S, del Prever AB, Palmerini E, et al: Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 52:581-584, 2009
81. Leavey PJ, Mascarenhas L, Marina N, et al: Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 51:334-338, 2008
82. Stahl M, Ranft A, Paulussen M, et al: Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549-553, 2011
83. Gardner SL, Carreras J, Boudreau C, et al: Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant 41:867-872, 2008
84. Erkizan HV, Scher LJ, Gamble SE, et al: Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle 10:3397-3408, 2011
85. Boro A, Prêtre K, Rechfeld F, et al: Smallmolecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. Int J Cancer 131:2153-2164, 2012
86. Grohar PJ, Griffin LB, Yeung C, et al: Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 13:145-153, 2011
87. DuBois SG, Krailo MD, Lessnick SL, et al: Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 52:324-327, 2009
88. Garofalo C, Mancarella C, Grilli A, et al: Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol 26:1603-1616, 2012
89. Brenner JC, Feng FY, Han S, et al: PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 72:1608-1613, 2012
90. Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575, 2012
91. Wang X, Weaver DT: The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res 1:301-327, 2011
92. Surdez D, Benetkiewicz M, Perrin V, et al: Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes ewing sarcoma growth. Cancer Res 72:4494-4503, 2012
93. Wittrant Y, Théoleyre S, Chipoy C, et al: RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704:49-57, 2004
94. Odri GA, Dumoucel S, Picarda G, et al: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 70:7610-7619, 2012
95. Kailayangiri S, Altvater B, Meltzer J, et al: The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 106:1123-1133, 2012
96. Scotlandi K, Perdichizzi S, Bernard G, et al: Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing's sarcoma. Eur J Cancer 42:91-96, 2006